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considerable interest [1]. Briefly, 29% of the superiority
of losartan (compared with atenolol) on the primary com-
posite end point was attributed to a fall in SUA.
In the Greek Atorvastatin and Coronary-Heart dis-
ease Evaluation (GREACE) study, using atorvastatin to
achieve the low-density lipoprotein cholesterol (LDL-C)
goal for high-risk patients (100 mg/dL; 2.6 mmol/L) was
associated with a significant (P < 0.0001) fall in SUA lev-
els [2]. In contrast, a significant (P < 0.0001) increase in
SUA occurred in the ‘usual care’ group, where the ma-
jority did not achieve the LDL-C target. Every 1 mg/dL
fall in SUA resulted in a decreased hazard ratio (0.76;
95% CI 0.62–0.89; P = 0.001) for vascular events. The fall
in SUA was attributed to a parallel reduction in serum
creatinine (SCr).
A decrease in SUA and SCr was seen in 103 periph-
eral arterial disease patients taking simvastatin [3]. In the
Heart Protection Study, the simvastatin group had a sig-
nificantly smaller (P < 0.0001) increase in SCr than the
placebo group [4].
In the LIFE study, the fall in SUA levels may be at-
tributed to the specific uricosuric action of losartan be-
cause the final SCr levels were similar in the losartan and
atenolol groups. Therefore, statins and losartan probably
lower SUA levels via different mechanisms, thus raising
the possibility of an additive effect.
The use of drugs that lower SUA levels may signifi-
cantly lower the risk of vascular events [5].
STELLA S. DASKALOPOULOU, VASILIOS G. ATHYROS,
MOSES ELISAF, and DIMITRI MIKHAILIDIS
London, United Kingdom; Thessaloniki and Ioannina, Greece
Correspondence to DP Mikhailidis, MD, FASA, FFPM, FRCP, FRC-
Path, Academic Head of Department, Department of Clinical Biochem-
istry (Vascular Disease Prevention Clinics), Royal Free Hospital campus,
Royal Free and University College Medical School, Pond Street, London
NW3 2QG, UK.
E-mail: MIKHAILIDIS@aol.com
REFERENCES
1. HOIEGGEN A, ALDERMAN MH, KJELDSEN SE, et al: LIFE Study Group:
The impact of serum uric acid on cardiovascular outcomes in the
LIFE study. Kidney Int 65:1041–1049, 2004
2. ATHYROS VG, ELISAF M, PAPAGEORGIOU AA, et al: GREACE Study
Collaborative Group: Effect of statins versus untreated dyslipidemia
on serum uric acid levels in patients with coronary heart disease. A
subgroup analysis of the GREek Atorvastatin and Coronary-heart-
disease Evaluation (GREACE) study. Am J Kidney Dis 43:589–599,
2004
3. YOUSSEF F, GUPTA P, SEIFALIAN AM, et al: The effect of short-term
treatment with simvastatin on renal function in patients with periph-
eral arterial disease. Angiology 55:53–62, 2003
4. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart
Protection Study of cholesterol-lowering with simvastatin in 5963
people with diabetes: A randomised placebo-controlled trial. Lancet
361:2005–2016, 2003
5. DASKALOPOULOU SS, MIKHAILIDIS DP, ATHYROS VG, et al: Fenofibrate
and losartan. Ann Rheum Dis 63:469–470, 2004
Heterozygous NPHS1 or
NPHS2 mutations in
responsive nephrotic syndrome
and the multifactorial origin of
proteinuria
To the Editor: Lahdenkari et al [1] described heterozy-
gous NPHS1 mutations in 2 out of 25 patients with min-
imal change nephropathy. Compound heterozygous mu-
tations were present in 2 adults with the same condition.
Similar clinical features were already reported in few
nephrotic patients with heterozygous NPHS2 mutations,
and in 1 child with heterozygous NPHS1 mutation asso-
ciated with the NPHS2 R229Q variant [2]. The body of
evidence on the topics is growing, and other confirmatory
papers are now appearing [3]. Therefore, while homozy-
gous and/or compound heterozygous mutations of these
2 genes are associated with strict steroid/cyclosporine re-
sistance, patients with a single mutation may respond to
therapy and have good long-term outcome. Because in-
herited conditions associated with NPHS1 or NPHS2 fol-
low a recessive trait, two issues remain unresolved. One
is why heterozygous carriers develop proteinuria, and the
second is the response to drugs.
As authors correctly discussed, mutations in other
genes could explain proteinuria as a part of a complex
inheritance (point 1). However, a complex inheritance
does not explain sensitivity to drugs that should better
be explained on the basis of a multifactorial mechanism
(point 2). Data on permeability activity in patients with
focal glomerulosclerosis and mutations of NPHS2 sup-
ports this possibility [4]. In spite of some unresolved prob-
lems, it seems worth mentioning the clinical impact of
these observations. They also suggest the implication of
nongenetic factors and open up to a multifactorial genesis
of proteinuria.
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Different meanings of
“glomerular tip lesion”
To the Editor: The term “glomerular tip lesion” [1] has
been used with three meanings:
(1) Our original description was in nephrotic patients
with structural changes at the tubular origin in glomeruli
that were otherwise normal. The clinical course resem-
bled that of minimal change nephropathy [2].
(2) We later realized that such changes were a com-
mon finding in many disorders, such as membranous
nephropathy [3]. These tip changes were not themselves a
disease, but could only be interpreted by consideration of
the rest of the glomerulus. Others have applied the term
“glomerular tip lesion” to these changes, irrespective of
the associated condition.
(3) We also reported tip changes in glomeruli show-
ing mesangial hypercellularity in the nephrotic syndrome,
sometimes with clinical progression [3, 4]. The ones who
did badly developed segmental sclerosis, corresponding
to many descriptions of “focal segmental glomeruloscle-
rosis.” We called the early stage early classical focal seg-
mental glomerulosclerosis [4].
‘Glomerular tip lesion,’ as defined by D’Agati et al [1],
also called “the tip variant of focal segmental glomeru-
losclerosis,” clearly includes our original definition, and
excludes tip changes in conditions such as membranous
nephropathy. Their definition allows mesangial hypercel-
lularity, and some of their patients may correspond to
early classical focal segmental glomerulosclerosis. Differ-
entiation between normal mesangium and mild mesan-
gial hypercellularity is arbitrary, but at the moment there
is no other satisfactory test to identify those who may
progress.
We agree with D’Agati et al that most patients with the
“glomerular tip lesion” by their definition, have steroid
responsive nephrotic syndrome and a good prognosis.
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Reply from the Authors
We agree with Dr. Howie that glomerular tip lesion
(GTL) may occur as a primary form in patients with idio-
pathic nephrotic syndrome, or may develop secondarily
in association with heavy proteinuria in diverse glomeru-
lar diseases [1]. We limited our study to primary GTL [2].
In our series, mesangial hypercellularity did not predict
outcome, defined as remission status at last follow-up.
None of our cases of primary GTL showed more than
mild mesangial hypercellularity, which was detected in
47% of GTL biopsies. Notably, the single GTL case that
progressed to end-stage renal disease lacked mesangial
hypercellularity.
Dr. Howie has observed that those cases with “struc-
tural changes at the tubular origin in glomeruli that were
otherwise normal” had a “clinical course resembling that
of minimal change disease.” Our data have shown, for
the first time, that routinely processed renal biopsies with
GTL frequently contained glomeruli with segmental le-
sions at other sites (peripheral or indeterminate, but not
perihilar), and most of these cases similarly followed a be-
nign course. Importantly, the segmental lesions were pre-
dominantly cellular (81%), rather than sclerosing. There
was no significant difference in remission status when
cases with GTL alone (26% of cases) were compared with
cases of GTL with segmental lesions at other glomerular
locations. Remission rate for GTL was better than for
idiopathic focal segmental sclerosis controls, but not as
good as that reported for adult minimal change disease.
For these reasons, we envision GTL as occupying an in-
termediate position, morphologically and clinically, in the
minimal change disease/focal segmental glomeruloscle-
rosis spectrum [3].
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